ImmuneOnco won the project supported by Shanghai Economic and Information Committee
On September 12 of 2017, ImmuneOnco Biopharmaceuticals Co., Ltd., an emerging biotech company fully focusing on discovery and development of tumor immunotherapy, announced that, one of its research projects won the supportion by Shanghai industrial transformation and upgrading of special funds project;the project No.: 17XI-23.
“The Bi-functional protein simultaneously targeting CD47/VEGF is one of many exciting programs in our preclinical development portfolio," said Dr. Wenzhi Tian, Chairman and Chief Executive Officer of ImmuneOnco. "The anti-angiogenesis activity of the protein will help shrink the tumor volume, making it more accessable to and easier for immune attack activated by the same protein blocking the SIRPa signals. We plan to file the IND of our novel bi-functional protein as early as late 2017 or early 2018." In preclinical studies, the combined inhibition of VEGF and SIRPa has resulted in significant anti-tumor activity in a variety of xenograft models.
Its first patent titled with “Recombinant Bi-functional Fusion Proteins, Preparations and Methods for Treating Disease” (U.S. Patent No. 14/666328) has been granted in the United States. This patent was originally invented by Macroimmune Inc which was acquired recently by ImmuneOnco. The new patent covers both composition-of-matter and method of treatment claims for the bi-functional protein.